Superior prognosis of neoadjuvant immunochemotherapy over neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma with pCR
The Journal of Thoracic and Cardiovascular Surgery · 2026-10
DOI: 10.1016/j.jtcvs.2026.10.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Thoracic and Cardiovascular Surgery, 2026-10. Verfasst von Pinhao Fang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China. Die Arbeit nennt 26 Literaturangaben. Gefördert von: CAMS Innovation Fund for Medical Sciences, Sichuan Province Science and Technology Support Program, Sichuan University West China Hospital.
Abstract (Originalsprache)
BACKGROUND: Neoadjuvant chemoradiotherapy (NCRT) is the standard regimen for locally advanced esophageal squamous cell carcinoma (ESCC), while neoadjuvant immunochemotherapy (NICT) has emerged as a promising alternative. Achieving a pathological complete response (pCR) after neoadjuvant therapy is associated with a favorable prognosis, yet whether the modality used to achieve pCR influences long-term outcomes remains unclear. METHODS: We retrospectively analyzed 332 patients with ESCC who attained pCR following neoadjuvant therapy (220 in the NCRT group and 112 in the NICT group). Prognostic outcomes, including short-term clinical outcomes, long-term survival, and recurrence patterns, were compared between the 2 groups. RESULTS: Among all patients with pCR, the NCRT group exhibited a significantly higher incidence of postoperative pneumonia compared with the NICT group (28.6% vs 14.3%, P = .004). Regarding recurrence patterns, the NCRT group showed higher rates of both local and distant recurrence. After multivariable adjustment, NICT conferred superior overall survival (OS) (hazard ratio [HR], 0.248; 95% CI, 0.076-0.809; P = .021) and disease-free survival (DFS) (HR, 0.215; 95% CI, 0.077-0.599; P = .003) relative to NCRT. CONCLUSIONS: Among patients with ESCC achieving pCR after neoadjuvant therapy, NICT was associated with significantly better OS and DFS, as well as a lower incidence of postoperative pneumonia, compared with NCRT. Given its survival benefit and favorable safety profile, NICT may be a preferred neoadjuvant strategy for selected patients, pending prospective validation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China.
- Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China. Electronic address: yongyuan@scu.edu.cn.
Förderung
- CAMS Innovation Fund for Medical Sciences
- Sichuan Province Science and Technology Support Program
- Sichuan University West China Hospital
Zitieren
APA
Fang, P., Xiao, X., Mao, C., Zhou, J., Yang, Y., Luan, S., Li, X., Zhang, H., & Yuan, Y. (2026). Superior prognosis of neoadjuvant immunochemotherapy over neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma with pCR. The Journal of Thoracic and Cardiovascular Surgery. https://doi.org/10.1016/j.jtcvs.2026.10.005
Vancouver
Fang P, Xiao X, Mao C, Zhou J, Yang Y, Luan S, et al. Superior prognosis of neoadjuvant immunochemotherapy over neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma with pCR. The Journal of Thoracic and Cardiovascular Surgery. 2026. doi:10.1016/j.jtcvs.2026.10.005
BibTeX
@article{Fang2026,
author = {Fang, Pinhao and Xiao, Xin and Mao, Chengyi and Zhou, Jianfeng and Yang, Yushang and Luan, Siyuan and Li, Xiaokun and Zhang, Haowen and Yuan, Yong},
title = {Superior prognosis of neoadjuvant immunochemotherapy over neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma with pCR},
journal = {The Journal of Thoracic and Cardiovascular Surgery},
year = {2026},
doi = {10.1016/j.jtcvs.2026.10.005}
}
EUVIMED